Clinical Trial Design Should Be Beyond Sponsor Control, UCSF Prof Urges
Clinical trial design should be carried out by investigators separate from the influence of drug sponsors, Thomas Bodenheimer, MD, University of California-San Francisco, told an HHS conference on human subject protection and financial conflict of interest.
You may also be interested in...
The increasing use of contract research organizations in the clinical trial process could increase skepticism among physicians and the public about study results, a New England Journal of Medicine "Health Policy Report" maintains.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials